Bladder Cancer Test From KDx Diagnostics Gets CE Mark

Jul 01, 2020

|

NEW YORK – KDx Diagnostics announced late on Tuesday that it has received the CE mark for its urine-based URO17 Bladder Cancer Recurrence test for bladder cancer.

As a result, the test can be marketed in Europe and other countries that recognize the designation.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Bladder Cancer Test From KDx Diagnostics Gets CE Mark

To read the full story....

Breaking News

Adaptive Biotechnologies Q2 Revenues Fall 5 Percent, Beat Analyst Estimates

Castle Biosciences Q2 Revenues Up 18 Percent

HTG Molecular Diagnostics, Qiagen Ink CDx Commercialization, Distribution Agreement

Helix Gets FDA Emergency Use Authorization for NGS-Based COVID-19 Test

BioMérieux, Beijing Wantai Coronavirus Antibody Tests Get FDA Emergency Use Authorization

Sysmex America to Distribute Siemens Urine Analyzer in North America

Case Study: An IVD Manufacturer’s Experience Building a Complete Sample-to-Result Workflow

What's Popular?

Guardant Health CDx Wins FDA Approval for First Liquid Biopsy NGS Tumor Profiling Assay

International Group Developing Point-of-Care Flow Cytometer for One-Day Diagnosis of Breast Cancer

Paige, Diatron Receive FDA Clearances in July

Guardant Health Colorectal Cancer Early-Detection Test Progresses Despite Pandemic Challenges

Natera Files Additional Patent Infringement Lawsuit Against ArcherDx

Sponsorships